Login to Your Account



FDA approves first ever China-made biologic for use in U.S. trials

By Cornelia Zou
Staff Writer

Wednesday, May 7, 2014
HONG KONG – The U.S. FDA has, for the first time ever, approved the use of a biologic product made by a Chinese company in U.S. investigational new drug trials. R&D services giant Wuxi Pharmatech Inc. (NYSE:WX) got the green light for HIV therapy drug ibalizumab (TMB-355), which it is manufacturing for Taiwan Taimed Biologics Inc., of Taipei, Taiwan.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription